Evidence map›Paper›PMID 30071892›Full record

ArticleArthritis research & therapy2018

Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway.

Glenn Haugeberg, Brigitte Michelsen, Stig Tengesdal, Inger Johanne Widding Hansen, Andreas Diamantopoulos, Arthur Kavanaugh

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Arthritis research & therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Glenn HaugebergDivision of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Servicebox 416, 4604, Kristiansand, Norway. glenn.haugeberg@sshf.no.
Brigitte MichelsenDivision of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Servicebox 416, 4604, Kristiansand, Norway.
Stig TengesdalDivision of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Servicebox 416, 4604, Kristiansand, Norway.
Inger Johanne Widding HansenDivision of Rheumatology, Department of Medicine, Hospital of Southern Norway Trust, Servicebox 416, 4604, Kristiansand, Norway.
Andreas DiamantopoulosDepartment of Rheumatology, Martina Hansens Hospital, Bærum, Norway.
Arthur KavanaughDivision of Rheumatology, Allergy, and Immunology, School of Medicine, University of California, San Diego, USA.
Hospital of Southern Norway · NOMartina Hansens Hospital · NOUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOver the last decade, a treat-to-target (T2T) strategy has been recommended for psoriatic arthritis (PsA) and new treatment options have become available. There is a lack of data on PsA regarding any changes that may have occurred over these past years. Thus, the main aim of this study was to look for changes in clinical disease status and treatment in a PsA outpatient clinic population monitored over the period 2008 to 2017.

methodsAnnual data collection included demographic data, laboratory (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)) and clinic measures of disease activity (e.g., 28 and 32 joint count Disease Activity Score (DAS28), Clinical Disease Activity Index (CDAI), and modified Disease Activity index for Psoriatic arthritis (DAPSA)), evaluator's global assessment, and patient-reported outcomes (PROs), including for example measures of physical function, pain, and patient global assessment. Disease-modifying antirheumatic drug (DMARD) use was also registered.

resultsIn the PsA outpatient clinic population over the 10-year period (annual mean number of patients, 331) the mean (standard deviation) age was 58.4 (12.4) years, disease duration was 9.6 (7.9) years, 49.4% were female, and 17.6% were current smokers. From 2008 to 2017, no statistically significant increase in remission rates was seen for DAPSA (13.5% and 22.0%) or Boolean remission (6.6% and 8.9%), whereas a statistically significant increase was seen for DAS28-ESR (36.8% and 50.6%) and CDAI (20.0% and 29.6%), but not for the last 5 years (DAS28-ESR, 42.3% and 50.6%; CDAI, 27.9% and 29.6%). Furthermore, over the 10-year period no significant improvement for PROs and no significant change in the use of synthetic (annual mean 53.0%) and biologic DMARDs (annual mean 29.9%) was found.

conclusionOur data suggest that even in the biologic treatment era there is an unmet need for treating PsA patients to target remission. New treatment options and the development of more feasible and valid outcome measures for use in a T2T strategy in ordinary clinical practice may in the future to further improve clinical outcomes in PsA.

Indexed as

AdultAgedAmbulatory Care FacilitiesAntirheumatic AgentsArthritis, PsoriaticFemaleFollow-Up StudiesHumansMaleMiddle AgedNorwayRemission InductionTreatment OutcomeAntirheumatic AgentsClinical outcomeDisease activityPatient-reported outcome measuresPsoriatic arthritisReal life registriesTreat to target

Identifiers

PMID30071892
PMCPMC6090981
OpenAlexW2887235192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.